BlinkBio
Jupiter
About BlinkBio
BlinkBio is a biotechnology company formed to exploit Bioorthogonal Linker (“BLink”) chemistries through their Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. It has assembled a modular toolbox of components allowing the design of Tunable Drug Conjugates a new class of Drug Conjugate therapies for the treatment of cancer. The company's TDC platform comprises a modular set of ligands, linkers, and payloads with aligned characteristics to enable both rapid payload release in the tumor and rapid systemic clearance of the parent drug conjugate. It was founded in 2009 and is headquartered in Jupiter, Florida.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $20.7M
- Funding stage: Seed
- Last round: Seed (May 2019)
- Website: blinkbioinc.com
- Phone: (800)983-8098
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/blinkbio-152825 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.